and Development of Novel Therapeutics
MEDFORD, Mass. and MALVERN, Pa., Nov. 6 /PRNewswire/ -- ArQule, Inc.
(Nasdaq: ARQL) and ViroPharma Incorporated (Nasdaq: VPHM) today announced a
collaboration for the discovery and development of novel therapeutics for the
treatment of diseases caused by RNA viruses. This collaboration will provide
ViroPharma with access to ArQule's Mapping Array(TM) program for the
identification of new lead compounds against ViroPharma's proprietary targets.
ArQule's Mapping Array(TM) program is comprised of libraries of novel,
diverse, small organic, pure compounds used for screening against biological
targets in new product discovery. If leads are identified, ArQule and
ViroPharma will use ArQule's Directed Array(TM) program to rapidly optimize
these lead compounds.
"ViroPharma focuses its antiviral drug discovery technologies and clinical
development efforts on diseases caused by RNA viruses, which are responsible
for the majority of human viral diseases," said Claude H. Nash, President, CEO
and Chairman of ViroPharma. "By utilizing ArQule's Mapping Array(TM) and
Directed Array(TM) programs to rapidly discover and optimize lead compounds,
we hope to decrease the amount of time necessary to develop treatments for RNA
"ViroPharma already has several ongoing clinical trials, and we look
forward to assisting them in discovering new products for viral disease," said
Eric B. Gordon, President and CEO of ArQule, Inc. "ArQule continues to apply
its proprietary technologies toward finding treatments for a wide range of
diseases, and this agreement enhances our presence in the viral area. The
Company is currently involved in the search for novel therapeutics to treat
over 10 different diseases; including cancer, infectious diseases, and
Under terms of the agreement, ViroPharma will employ its proprietary
screens to discover potential leads from ArQule's Mapping Array(TM) compound
sets. Once active leads are identified, the companies will optimize such
leads using ArQule's Directed Array(TM) program and ViroPharma's expertise in
virology. ViroPharma and ArQule will share development and commercialization
rights for the compounds through IND approval.
ViroPharma Incorporated is engaged in the discovery and development of
proprietary antiviral pharmaceuticals for treatment of diseases caused by RNA
viruses. RNA viruses are responsible for the majority of human viral
diseases. ViroPharma has focused its initial drug development and discovery
activities on a number of RNA virus diseases, including viral meningitis,
viral syndrome, hand-foot-and-mouth disease, the common cold, influenza,
hepatitis C and viral pneumonia.
ArQule, Inc. is a leading chemistry company in accelerated drug discovery
using its high throughput lead generation and lead optimization technologies.
ArQule provides new pathways to product discovery by integrating five core
technologies -- modular building block technology, structure-guided design,
high speed parallel chemical synthesis, information technology and an
Automated Molecular Assembly Plant (AMAP(TM)) parallel synthesis system to
accelerate the identification and optimization of drug and product development
candidates in the pharmaceutical, biotechnology, and agrochemical industries.
ArQule is based in Medford, Massachusetts.
Statements in this press release that are not strictly historical are
"forward looking" statements as defined in the Private Securities Litigation
Reform Act of 1995. The actual results may differ from those projected in the
forward looking statement due to risks and uncertainties that exist in the
operations and business environment of ArQule and ViroPharma, described more
fully in ArQule's Form 10-K for the year ended December 31, 1996 and the
Registration Statement on Form S-1 dated April 4, 1997, filed with the
Securities and Exchange Commission, and in ViroPharma's Registration Statement
on Form S-1 dated July 23, 1997 filed with the Securities and Exchange
SOURCE ArQule, Inc.
/CONTACT: Eric B. Gordon, President and CEO of ArQule, 781-395-4100 or
Claude H. Nash, President, CEO and Chairman of ViroPharma, 610-651-0200 or
Investor Relations: Lucy L. Morrison, Manager of Feinstein Kean Partners,
CO: ArQule, Inc.; ViroPharma Incorporated
ST: Massachusetts, Pennsylvania
-0- (PRN) Nov/06/97 08:29
EOS (PRN) Nov/06/97 08:29 **
Press spacebar to pause and continue. Press esc to stop.